Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 15 , ISSUE 6 ( November-December, 2023 ) > List of Articles

ORIGINAL RESEARCH

Impact of Antenatal Corticosteroids on Glycemic Variations in Gestational Diabetes Mellitus: A Single Center Observational Study

Nagarathna Gopal, KMD Sudeep, Sudhir Prabhu Haladi, Ashwini Patil

Keywords : Antenatal corticosteroids, Gestational diabetes mellitus, Insulin therapy, Medical nutritional therapy

Citation Information : Gopal N, Sudeep K, Haladi SP, Patil A. Impact of Antenatal Corticosteroids on Glycemic Variations in Gestational Diabetes Mellitus: A Single Center Observational Study. J South Asian Feder Obs Gynae 2023; 15 (6):647-653.

DOI: 10.5005/jp-journals-10006-2305

License: CC BY-NC 4.0

Published Online: 04-12-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Aim: The study evaluated the effect of prophylactic antenatal corticosteroids (ACSs) on maternal blood glucose (MBG) changes and insulin requirement in gestational diabetes mellitus (GDM). Materials and methods: Patients with GDM received a conventional ACS regimen. Pre-meal glucose levels determined initiation of insulin or dose titration if already on insulin. All were monitored for 72 hours after the first dose of ACS. From day 3, fasting blood glucose, one hour post-meal glucose levels were assessed. Glycemic monitoring was continued for five days in those who had hyperglycemia during the first 72 hours after ACS. Results: Of the 52 patients, 12 required insulin for the first time and 14 were already on it before ACS, remaining were managed with medical nutritional therapy (MNT). Maternal blood glucose declined from day 3 onwards, euglycemic status was reached on day 4 and sustained on day 5. There was no significant change in the mean MBG during the first two days following ACS, but a gradual decline from day 3 was noticeable. The mean MBG change was independent of duration. There was a significant difference between the average insulin requirements. There was no fetal loss. Conclusion: Antenatal corticosteroid-induced hyperglycemia increases the requirement of insulin, or add on oral hypoglycemic agents. Well-controlled glycemic status is achievable with MNT alone or in combination with pharmacotherapy under continued monitoring. Clinical significance: Continuous monitoring, MNT to meet the increased nutritional needs, not increase MBG levels at the same time, and add on pharmacotherapy should be included in the treatment strategy.


HTML PDF Share
  1. International Diabetes Federation. IDF Diabetes Atlas, 9th edition. Brussels, Belgium: International Diabetes Federation; 2019. Available from: https://diabetesatlas.org/idfawp/resource-files/2019/07/IDF_diabetes_atlas_ninth_edition_en.pdf.
  2. Seshiah V, Balaji V, Balaji MS, et al. Prevalence of GDM in South India (Tamil Nadu). A Community Based Study. J Assoc Phys India 2008;56:329–333. PMID: 18700640.
  3. Swaminathan G, Swaminathan A, Corsi DJ. Prevalence of gestational diabetes in India by individual socioeconomic, demographic, and clinical factors. JAMA Netw Open 2020;3:e2025074. DOI: 10.1001/jamanetworkopen.2020.25074.
  4. Agarwal MM, Dhatt GS, Othman Y. Gestational diabetes: Differences between the current international diagnostic criteria and implications of switching to IADPSG. J Diabetes Complicat 2015;29(4):544–549. DOI: 10.1016/j.jdiacomp.2015.03.006.
  5. National Health Mission. National Guidelines for Diagnosis & Management of Gestational Diabetes Mellitus. New Delhi: Government of India in Collaboration with UNICEF; 2014. Available online: http://nrhm.gov.in/images/pdf/programmes/maternal-health/guidelines/National_Guidelines_for_Diagnosis_&_Management_of_Gestational_Diabetes_Mellitus.pdf. Last accessed: June 2020.
  6. Li KT, Naik S, Alexander M, et al. Screening and diagnosis of gestational diabetes in India: A systematic review and meta-analysis. Acta Diabetol 2018;55(6):613–625. DOI: 10.1007/s00592-018-1131-1.
  7. Malhotra S, Kant S, Kumar R, et al. Gestational diabetes mellitus among pregnant women attending ante-natal clinic at a secondary care health facility in Haryana, India. Cureus 2022;14(5): e25452. DOI: 10.7759/cureus.25452.
  8. Gracelyn LJ, Saranya N. Prevalence of gestational diabetes mellitus in antenatal women and its associated risk factors. Intl J Reprod Contracept Obstet Gynecol 2016;5(2):285–291. DOI: 10.18203/2320-1770.ijrcog20160081.
  9. Raja MW, Baba TA, Hanga AJ, et al. A study to estimate the prevalence of gestational diabetes mellitus in an urban block of Kashmir valley (North India). Int J Med Sci Public Health 2014;3:191–196. DOI: 10.5455/ijmsph.2013.211120131.
  10. Seshiah V, Balaji V, Balaji S, et al. Gestational diabetes mellitus in India. JAPI 2004;52:707–711. PMID: 15839447.
  11. Mithal A, Bansal B, Kalra S. Gestational diabetes in India: Science and society. Indian J Endocrinol Metab 2015;19(6):701–704. DOI: 10.4103/2230-8210.164031.
  12. Swami SR, Mehetre R, Shivane V, et al. Prevalence of carbohydrate intolerance of varying degrees in pregnant females in western India (Maharashtra)—a hospital-based study. J Indian Med Assoc 2008;106:712–714, 735. PMID: 19368095.
  13. McGoldrick E, Brown J, Middleton P, et al. Antenatal corticosteroids for fetal lung maturation: An overview of Cochrane reviews. Cochrane Database Sys R 2016;4:CD012156. DOI: 10.1002/14651858. CD012156.
  14. Refuerzo JS, Garg A, Rech B, et al. Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: A pilot study. Am J Perinatol 2012;29:335–338. DOI: 10.1055/s-0031-1295642.
  15. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynaecol 1995;173(1):254–262. DOI: 10.1016/0002-9378(95)90210-4.
  16. US Preventive Services Task Force. US preventive services task force screening for gestational diabetes. Topic page Rockville, Md Agency for Healthcare Research and Quality 2008. Available from: http://www.ahrq.gov/clinic/uspstf/uspsgdm.htm. Last accessed: Nov 3, 2022.
  17. American College of Obstetricians and Gynecologists Committee on Practice Bulletins–Obstretrics. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001;98:525–538. PMID: 11547793.
  18. Miracle X, Di Renzo GC, Stark A, et al. Coordinators Of World Associatin of Perinatal Medicine Prematurity Working Group. Guideline for the use of antenatal corticosteroids for fetal maturation. J Perinat Med 2008;36(3):191–196. DOI: 10.1515/JPM.2008.032.
  19. Oliveros E, Somers VK, Sochor O, et al. The concept of normal weight obesity. Prog Cardiovasc Dis 2014;56(4):426–433. DOI: 10.1016/j.pcad.2013.10.003. DOI: 10.1016/j.pcad.2013.10.003.
  20. Mathiesen ER, Christensen AB, Hellmuth E, et al. Insulin dose during glucocorticoid treatment for fetal lung maturation in diabetic pregnancy: test of an algorithm [correction of analgoritm]. Acta Obstet Gynecol Scand 2002;81(9):835–839. DOI: 10.1034/j.1600-0412.2002.810906.x.
  21. Kalra S, Kalra B, Gupta Y. Glycemic management after antenatal corticosteroid therapy. N Am J Med Sci 2014;6(2):71–76. DOI: 10.4103/1947-2714.127744. PMID: 21966858.
  22. Ramírez-Torres MA, Pérez-Monter SE, Espino y Sosa S, et al. Effect of betamethasone in blood glucose levels in pregnant diabetic women at risk of preterm birth. Ginecol Obstet Mex 2011;79(9):565–571.
  23. Kreiner A, Gil K, Lavin J. The effect of antenatal corticosteroids on maternal serum glucose in women with diabetes. Open J Obstet Gynecol 2012;2(2):112–115. DOI: 10.4236/ojog.2012.22021.
  24. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: Summary of evidence and consensus recommendations for care. Diabetes Care 2008;31(5):1060–1079. DOI: 10.2337/dc08-9020.
  25. Rosenstein MG, Cheng YW, Snowden JM, et al. The risk of stillbirth and infant death stratified by gestational age in women with gestational diabetes. Am J Obstet Gynecol 2012;206(4):309.e1–7. DOI: 10.1016/j.ajog.2012.01.014.
  26. Schmidt MI, Duncan BB, Reichelt AJ, et al. Brazilian Gestational Diabetes Study Group. Gestational diabetes mellitus diagnosed with a 2-h 75-g oral glucose tolerance test and adverse pregnancy outcomes. Diabetes Care 2001;24(7):1151–1155. DOI: 10.2337/diacare.24.7.1151.
  27. Remsberg KE, McKeown RE, McFarland KF, et al. Diabetes in pregnancy and cesarean delivery. Diabetes Care 1999;22(9):1561–1567. DOI: 10.2337/diacare.22.9.1561.
  28. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358(19):1991–2002. DOI: 10.1056/NEJMoa0707943.
  29. Ye W, Luo C, Huang J, et al. Gestational diabetes mellitus and adverse pregnancy outcomes: Systematic review and meta-analysis. BMJ 2022;377:e067946. DOI: 10.1136/bmj-2021-067946.
  30. Ali H, Salama H, Robertson N, et al. Antenatal corticosteroids and short-term neonatal outcomes in term and near-term infants of diabetic mothers. Analysis of the Qatar PEARL-peristat registry. J Perinat Med 2020;49(3):377–382. DOI: 10.1515/jpm-2020-0249.
  31. Paul R, Murugesh C, Chepulis L, et al. Should antenatal corticosteroids be considered in women with gestational diabetes before planned late gestation caesarean section. Aust N Z J Obstet Gynaecol 2019;59(3):463–466. DOI: 10.1111/ajo.12963.
  32. McKinzie AH, Yang Z, Teal E, et al. Are newborn outcomes different for term babies who were exposed to antenatal corticosteroids? Am J Obstet Gynecol 2021;225(5):536.e1–536.e7. DOI: 10.1016/j.ajog.2021.04.251.
  33. Krispin E, Hochberg A, Chen R, et al. Neonatal outcome in gestational-diabetic mothers treated with antenatal corticosteroids delivering at the late preterm and term. Arch Gynecol Obstet 2018;298(4):689–695. DOI: 10.1007/s00404-018-4848-8.
  34. Dude AM, Yee LM, Henricks A, et al. Neonatal hypoglycemia after antenatal late preterm steroids in individuals with diabetes. J Perinatol 2021;41(12):2749–2753. DOI: 10.1038/s41372-021-01267-4.
  35. Battarbee AN, Sandoval G, Grobman WA, et al. Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units (MFMU) Network. Antenatal corticosteroids and preterm neonatal morbidity and mortality among women with and without diabetes in pregnancy. Am J Perinatol 2022;39(1):67–74. DOI: 10.1055/s-0040-1714391.
  36. Thevathasan I, Karahalios A, Unterscheider J, et al. Neonatal outcomes following antenatal corticosteroid administration prior to elective caesarean delivery in women with pre-gestational diabetes: A retrospective cohort study. Aust N Z J Obstet Gynaecol 2023;63(1):93–98. DOI: 10.1111/ajo.13586.
  37. Osteen SJ, Yang Z, Mckinzie AH, et al. Long-term childhood outcomes for babies born at term who were exposed to antenatal corticosteroids. Am J Obstet Gynecol 2022:S0002–9378(22)00580-4. DOI: 10.1016/j.ajog.2022.07.026.
  38. Hong JGS, Tan PC, Kamarudin M, et al. Prophylactic metformin after antenatal corticosteroids (PROMAC): A double blind randomized controlled trial. BMC Pregnancy Childbirth 2021;21(1):138. DOI: 10.1186/s12884-021-03628-5.
  39. Kaushal K, Gibson JM, Railton A, et al. A protocol for improved glycaemic control following corticosteroid therapy in diabetic pregnancies. Diabet Med 2003;20(1):73–75. DOI: 10.1046/j.1464-5491.2003.00853.x.
  40. Rowe CW, Watkins B, Brown K, et al. Efficacy and safety of the pregnancy-IVI, an intravenous insulin protocol for pregnancy, following antenatal betamethasone in type 1 and type 2 diabetes. Diabet Med 2021;38:e14489. DOI: 10.1111/dme.14489.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.